This review summarizes the evidence on nuclear receptors (NRs),
such as glucocorticoid receptor, mineralocorticoid receptor, estrogen receptor,
aryl hydrocarbon receptor, and peroxisome proliferator-activated receptor, in
modulating the inflammasome activity and depression-associated behaviors. Major
depressive disorder (MDD) is highly prevalent and is a significant cause of
mortality and morbidity worldwide. Currently, conventional pharmacological
treatments for MDD produce temporary remission in < 50% of patients;
therefore, there is an urgent need for a wider spectrum of novel
antidepressants to target newly discovered underlying disease mechanisms.
Another important hypothesis of depression, several lines of evidence have
established an association between MDD and the neuroimmune pathway, although
some psychiatrists have argued about the causal relationship between
inflammation and depression. Accumulated evidence has shown that immune
inflammation, particularly inflammasome activity, plays an important role in
the pathophysiology of MDD. This review provides evidence from an endocrine
perspective to understand the role of activated NRs in the pathophysiology of
MDD and to provide insight into the discovery of antidepressants with novel
mechanisms for this devastating disorder. Cumulative studies have shown that
activation of the NRs may directly change the activity of inflammasomes to
modulate the levels of mature forms of caspase-1 and IL-1
Author
(s) Details
Han Wang
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Wei-Jing Kan
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Yuan Feng
The National Clinical Research Center for Mental Disorders & Beijing Key
Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Lei Feng
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Yang Yang
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088, Beijing
Province, China.
Pei Chen
The National Clinical Research Center for Mental Disorders & Beijing Key
Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Jing-Jie Xu
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Tian-Mei Si
Department of Clinical Psychopharmacology, Peking University, Institute of
Mental Health, Beijing 100191, Beijing
Province, China.
Ling Zhang
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders,
Beijing Anding Hospital, Beijing 100088, Beijing Province, China.
Gang Wang
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China.
Jing Du
The National Clinical Research Center for Mental Disorders & Beijing
Key Laboratory of Mental Disorders, Beijing Anding Hospital, Beijing 100088,
Beijing Province, China and State Key Laboratory for Conservation and
Utilization of Bio-Resources in Yunnan, Yunnan University, Kunming 650091,
Yunnan Province, China.
Please see the book here:- https://doi.org/10.9734/bpi/mmrnp/v7/2092
